COVID-19 Prevalence and Survival Outcome in Pediatric Cancer Patients Undergoing Chemotherapy: A Study from Tertiary Cancer Center of North-East India

Background: Pediatric cancer patients are considered one of vulnerable group for Covid-19 infections and its associated complication. We assessed prevalence implications in pediatric NorthEast India. Methods: Retrospective study was conducted between July 2020 to June 2021 at Dr B Borooah Cancer Institute (BBCI), Guwahati, Assam, Medical records the childhood were analyzed. All who tested SARS-CoV-2 collected. with age eighteen years included. Results: Fifty two out 701 (7%) children found be positive SARS-CoV2 by RT-PCR testing. Among COVID-19 patients, median six years. In group, thirty (57.6 %) suffering from hematological malignancy twenty (42.4%) have solid malignancy. malignancies; acute lymphoblastic leukemia (ALL) comprises 70% (21), myeloid (AML) 16.66% (5) lymphoma accounting 13.33%. Fever, cough sore throat presenting symptom majority patients. Survival outcome has shown statistically significant association (p=0.0001) negative Eight deaths occurred but there only death Conclusion: risk significantly higher compared malignancies receiving intensive chemotherapy.